Can heart failure worsen after Watchman left atrial appendage closure implantation in an older patient with atrial fibrillation, hypertension, coronary artery disease, and mild‑to‑moderate heart failure?

Can Heart Failure Worsen After Watchman Implantation?

Heart failure does not appear to worsen after Watchman (or other left atrial appendage closure devices) implantation, based on the highest quality evidence from a large randomized trial. 1

Key Evidence on Heart Failure Risk

The most definitive data comes from the LAAOS III trial (2025), which randomized 4,811 patients with atrial fibrillation undergoing cardiac surgery to left atrial appendage occlusion (LAAO) versus no occlusion. 1 This study specifically examined heart failure outcomes and found:

• No increased risk of HF-related hospitalization or death with LAAO (8.8% vs 7.8%; HR 1.12,95% CI 0.92-1.37, p=0.25) 1
• No difference in early HF events within 30 days (1.6% vs 1.1%; p=0.12) 1
• No difference in late HF events beyond 30 days (7.6% vs 7.1%; p=0.57) 1
• Consistent results across all subgroups, including patients with pre-existing heart failure (57% of the cohort had prior HF) 1

This addresses a theoretical concern that removing the LAA—which produces natriuretic peptides—might worsen heart failure, but the trial definitively shows this does not occur clinically. 1

Safety Profile in Heart Failure Patients

Periprocedural Safety

Percutaneous LAAO (including Watchman) appears safe in patients with existing heart failure: 2, 3

• No difference in inpatient mortality between HF and non-HF patients undergoing LAAC 2
• No difference in cardiac complications during the procedure 2
• Slightly higher non-cardiac complications (acute kidney injury, respiratory failure) in HF patients, likely related to underlying comorbidities rather than the device itself 2
• High procedural success rates (96-99.5%) even in patients with heart failure 3

Long-Term Outcomes in Heart Failure Patients

While HF patients have higher overall mortality after LAAO, this reflects their underlying disease burden rather than device-related harm: 3

• Higher MACCE rates (31.9% vs 15.1%) and mortality (24.2% vs 7%) in CHF patients during long-term follow-up 3
• Heart failure itself is an independent predictor of mortality (HR 3.23), not the LAAO procedure 3
• The increased mortality is attributed to comorbidities associated with CHF, not worsening from the device 3

Clinical Context from Guidelines

The 2024 ESC guidelines provide limited guidance on LAAO, noting it may be considered (Class IIb) in AF patients with contraindications to long-term anticoagulation. 4 The guidelines acknowledge uncertainty about LAAO's role in current practice given that DOACs have similar bleeding rates to aspirin. 4

Importantly, the guidelines do not identify heart failure worsening as a concern with LAAO devices. 4

Special Considerations for Older Patients

In elderly patients (≥80 years), which matches your clinical scenario: 5, 6

• Similar in-hospital mortality compared to younger patients 5
• Increased periprocedural complications (stroke/TIA 1.22% vs 0.77%, bleeding, vascular complications) 5
• Higher 30-day readmission rates (9.91% vs 8.4%) 5
• Overall procedural success remains high (90.1%) in octogenarians 6

These data suggest LAAO should be carefully considered in very elderly patients, weighing procedural risks against benefits, but heart failure worsening is not a primary concern. 5

Common Pitfalls to Avoid

• Do not discontinue guideline-directed medical therapy (GDMT) for heart failure after LAAO implantation, as patients remain at risk for HF events even with improved ejection fraction 7
• Monitor for non-cardiac complications (renal dysfunction, respiratory issues) in HF patients post-procedure rather than focusing solely on cardiac outcomes 2
• Recognize that higher mortality in HF patients reflects their underlying disease, not device-related harm—this should inform realistic prognostic discussions 3